TGFB1 and hepatocellular carcinoma: This study indicated that the combination treatment strategy using SB431542 to block TGF-β1-induced EMT, coupled with immune checkpoint inhibition through PD-L1 and CD73 knockdown alongside sorafenib, could effectively target an invasive, drug-resistant subgroup of CSCs derived from HCC.